Response of B-cell lymphoma to a combination of bispecific antibodies and saporin

WHO Handbook for Reporting Results of Cancer Treatment

1982 • 2,214 citations

Phase I immunotoxin trial in patients with B-cell lymphoma.

1991 • 289 citations

Preparation and performance of bispecific F(ab' gamma)2 antibody containing thioether-linked Fab' gamma fragments.

1987 • 267 citations

Ribosome-inactivating proteins from the seeds of Saponaria officinalis L. (soapwort), of Agrostemma githago L. (corn cockle) and of Asparagus officinalis L. (asparagus), and from the latex of Hura crepitans L. (sandbox tree)

1983 • 225 citations

A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy

1993 • 221 citations

Response of refractory Hodgkin's disease to monoclonal anti-CD30 immunotoxin

1992 • 215 citations

Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin.

1987 • 212 citations

Immunotoxins: magic bullets or misguided missiles?

1993 • 209 citations

A phase I study of an anti-CD22-deglycosylated ricin A chain immunotoxin in the treatment of B-cell lymphomas resistant to conventional therapy

1993 • 185 citations

Serotherapy of B-cell neoplasms with anti-B4-blocked ricin: a phase I trial of daily bolus infusion

1992 • 174 citations

Phase I evaluation of an anti-breast carcinoma monoclonal antibody 260F9-recombinant ricin A chain immunoconjugate.

1989 • 122 citations

Immunotoxins: a clinical review of their use in the treatment of malignancies.

1989 • 108 citations

Phase I study of monoclonal antibody-ricin A chain immunotoxin XomaZyme-791 in patients with metastatic colon cancer.

1989 • 88 citations

Therapeutic strategies with monoclonal antibodies and immunoconjugates.

1988 • 76 citations

Value of monoclonal anti-CD22 (p135) antibodies for the detection of normal and neoplastic B lymphoid cells

1987 • 71 citations

Bispecific F(ab' gamma)2 antibody for the delivery of saporin in the treatment of lymphoma.

1988 • 68 citations

Antibody Toxin Conjugates: A Perspective

2015 • 66 citations

Initial experience in treating human lymphoma with a chimeric univalent derivative of monoclonal anti-idiotype antibody

1987 • 59 citations

Emergence of immunoglobulin variants following treatment of a B cell leukemia with an immunotoxin composed of antiidiotypic antibody and saporin.

1987 • 44 citations

Delivery of saporin to human B-cell lymphoma using bispecific antibody: targeting via CD22 but not CD19, CD37, or immunoglobulin results in efficient killing.

1993 • 44 citations

Hepatotoxicity of immunotoxins made with saporin, a ribosome-inactivating protein fromSaponaria officinalis

1987 • 36 citations

Delivery of the ribosome-inactivating protein, gelonin, to lymphoma cells via CD22 and CD38 using bispecific antibodies

1995 • 33 citations

Initial experience in treating human lymphoma with a combination of bispecific antibody and saporin.

1992 • 33 citations

Treatment of B-cell lymphomas with combination of bispecific antibodies and saporin

1995 • 32 citations

Cooperative mixtures of bispecific F(ab')2 antibodies for delivering saporin to lymphoma in vitro and in vivo.

1991 • 27 citations

Tumour immunobiology: A practical approach

1994 • 24 citations

Covalent binding of human alpha 2-macroglobulin to deglycosylated ricin A chain and its immunotoxins.

1991 • 22 citations

Characterization of a Human B Lymphocyte-Specific Antigen Defined by Monoclonal Antibodies HD6 and HD39

1986 • 19 citations

Tumour Immunobiology: A Practical Approach

1994 • 17 citations

A simple technique for the determination of κ and λ immunoglobulin light chain expression by B cells in whole blood

1992 • 7 citations